Compare Stocks: NTOG, SYN, STA, and PET

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PET Wag! Group	$0.05	$0.10	$0.04 ▼ $0.27	$2.38M	1.66	11.43 million shs	N/A
STA Sanatana Resources	C$0.62 +1.6%	C$0.62	C$0.08 ▼ C$0.94	C$41.62M	6.495454	119,807 shs	193,172 shs
SYN Synthetic Biologics		$0.00	$0.97 ▼ $4.56	$16.16M	1.38	197,338 shs	57,700 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PET Wag! Group	0.00%	0.00%	0.00%	0.00%	-2.49%
STA Sanatana Resources	0.00%	0.00%	0.00%	0.00%	-15.07%
SYN Synthetic Biologics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PET Wag! Group	$0.05	$0.10	$0.04 ▼ $0.27	$2.38M	1.66	11.43 million shs	N/A
STA Sanatana Resources	C$0.62 +1.6%	C$0.62	C$0.08 ▼ C$0.94	C$41.62M	6.495454	119,807 shs	193,172 shs
SYN Synthetic Biologics		$0.00	$0.97 ▼ $4.56	$16.16M	1.38	197,338 shs	57,700 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PET Wag! Group	0.00%	0.00%	0.00%	0.00%	-2.49%
STA Sanatana Resources	0.00%	0.00%	0.00%	0.00%	-15.07%
SYN Synthetic Biologics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
PET Wag! Group	N/A	N/A	N/A
STA Sanatana Resources	N/A	N/A	N/A
SYN Synthetic Biologics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PET Wag! Group	$70.51M	0.03	N/A	N/A	($0.01) per share	-4.69
STA Sanatana Resources	N/A	N/A	C$0.13 per share	4.71	C$0.01 per share	N/A
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	$4.95 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PET Wag! Group	-$17.57M	-$0.39	N/A	N/A	N/A	-29.17%	N/A	-58.54%	N/A
STA Sanatana Resources	-C$2.27M	-C$0.40	N/A	N/A	N/A	N/A	-58.40%	-54.68%	N/A
SYN Synthetic Biologics	-$14.27M	-$1.21	N/A	N/A	N/A	N/A	-26.14%	-22.74%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PET Wag! Group	N/A	N/A	N/A	N/A	N/A
STA Sanatana Resources	N/A	N/A	N/A	N/A	N/A
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PET Wag! Group	N/A	0.46	0.46
STA Sanatana Resources	3.47	5.53	2.01
SYN Synthetic Biologics	N/A	4.14	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PET Wag! Group	86.16%
STA Sanatana Resources	0.62%
SYN Synthetic Biologics	74.38%

Insider Ownership

Company	Insider Ownership
PET Wag! Group	20.70%
STA Sanatana Resources	10.34%
SYN Synthetic Biologics	2.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PET Wag! Group	90	50.74 million	40.24 million	Not Optionable
STA Sanatana Resources	3	67.13 million	N/A	Not Optionable
SYN Synthetic Biologics	16	15.84 million	15.50 million	Not Optionable

NTOG, SYN, STA, and PET Headlines

Recent News About These Companies

Isto Biologics Strengthens its Bone Graft Substitutes Platform with the Acquisition of NovaBone

August 4, 2026 | finance.yahoo.com

Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care Solutions

July 21, 2026 | markets.businessinsider.com

Computational design drives new generation of synthetic promoters

March 27, 2026 | drugtargetreview.comD

Gene Synthesis Market Comprehensive Industry Analysis, Trends, and Future Outlook

February 25, 2026 | pharmiweb.comP

6 ways biologics is advancing in spine

February 19, 2026 | beckersspine.comB

Stopping Biologics Before Surgery May Raise Flare Risk in RA

January 27, 2026 | rheumatologyadvisor.comR

Study Shows NanoFuse(R) Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass Alone

January 26, 2026 | marketwatch.com

MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™

January 15, 2026 | uk.finance.yahoo.com

MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix(TM)

January 15, 2026 | marketwatch.com

Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production

January 13, 2026 | pharmiweb.comP

4 orthobiologics updates

December 18, 2025 | beckersspine.comB

Exposure to Some DMARDs in Fathers-to-Be Tied to Birth Risks

December 2, 2025 | medscape.comM

Relapse in Juvenile Idiopathic Arthritis After Stopping DMARDs: Key Factors Found

December 1, 2025 | medscape.comM

Constructive Bio and RxCelerate partner to develop biologic therapeutic candidates

November 19, 2025 | businessweekly.co.ukB

RA Onset Age Doesn’t Affect Non-TNF Agents’ Infection Risk

October 29, 2025 | medscape.comM

Aurora Spine Launches New Biologics Portfolio

October 28, 2025 | markets.businessinsider.com

Wound Care Biologics Market Size Worth USD 11.22 Billion by 2034

October 27, 2025 | finance.yahoo.com

Study assesses SI joint outcomes between surgeons, pain physicians

October 21, 2025 | beckersspine.comB

Active Pharmaceutical Ingredients (API) Market worth $198.39 billion by 2030 with 6.6% CAGR | MarketsandMarkets™

October 15, 2025 | finance.yahoo.com

Rheumatoid Arthritis Linked to Elevated Pneumonia Risk, Especially in Seropositive Disease

October 1, 2025 | ajmc.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NTOG, SYN, STA, and PET Company Descriptions

Wag! Group NASDAQ:PET

Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and pet insurance comparison tools. The company was founded in 2014 and is headquartered in San Francisco, California.

Sanatana Resources CVE:STA

C$0.62 +0.01 (+1.64%)

As of 10/7/2025

Sanatana Resources Inc., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties. It explores for copper and gold. The company entered in an option agreement to acquire 80% interest in the Oweegee Dome project covering an area of approximately 31,077 hectares located in in Golden Triangle in British Columbia; and 100% interest in the Empress Property, as well as asset purchase agreement to acquire the Santoy Property comprising 32 cell mining claims covering an area of approximately 551 hectares located in in Ontario. It also holds interests in the Fortune Project consisting of 100% interest in the Enid property, which comprises 41 mineral claims in the Timmins, Ontario region. The company was formerly known as Sanatana Diamonds Inc. and changed its name to Sanatana Resources Inc. in April 2011. Sanatana Resources Inc. was incorporated in 2004 and is headquartered in Vancouver, Canada.

Synthetic Biologics NYSEAMERICAN:SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTOG, SYN, STA, and PET Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NTOG, SYN, STA, and PET Company Descriptions

Wag! Group NASDAQ:PET

Sanatana Resources CVE:STA

Synthetic Biologics NYSEAMERICAN:SYN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTOG, SYN, STA, and PET Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NTOG, SYN, STA, and PET Company Descriptions

Wag! Group NASDAQ:PET

Sanatana Resources CVE:STA

Synthetic Biologics NYSEAMERICAN:SYN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools